Indian Economy News

Serum, Bharat Biotech to work together to develop, supply COVID-19 vaccines

  • IBEF
  • January 6, 2021

On Tuesday, the Serum Institute of India (SII) and Bharat Biotech said they will work together in India and globally to produce, manufacture and supply COVID-19 vaccines.

SII CEO, Mr. Adar Poonawalla and Bharat Biotech Chairman and Managing Director, Mr. Krishna Ella confirmed their joint aim to produce, manufacture and supply COVID-19 vaccines for India and the world.

They acknowledged that saving lives and livelihoods in India and globally was the most significant task in front of them.

Vaccines are beneficial for global public health and have the potential to save lives and, at the earliest, boost the return to economic normalcy. Now that two EUA (emergency use authorisation) COVID-19 vaccines have been released in India, the focus is on the manufacture, supply and distribution of COVID-19 vaccines.

Emergency usage authorisation for Oxford-Covishield AstraZeneca's and Bharat Biotech's Covaxin was issued by the DCGI on Sunday.

They said, “Both of our organisations are actively engaged in this operation and consider it our responsibility to ensure a seamless rollout of vaccines for the nation and the world at large. As expected, each of our companies is continuing their COVID-19 vaccine development activities.”

They added, “Companies are well aware of the value of vaccines for individuals and nations alike, and hereby share our shared commitment to ensuring global access to our COVID-19 vaccines.”

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.

Partners
Loading...